Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer
Hasegawa, T.; Teraoka, H.; Mori, T.; Kinoshita, H.; Nakamoto, K.; Noda, E.; Hirakawa, K.; Ohira, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(13): 2407-2409
2019
ISSN/ISBN: 0385-0684 PMID: 32156947 Document Number: 699421
Although the S-1 plus CDDP(SP)regimen is the standard treatment for advanced gastric cancer, hydration and admission have been recommended after cisplatin has been administered. In this study, short hydration(SH)method was used and SP was administered in outpatient settings. We evaluated renal toxicity of cisplatin in the SH-SP regimen at our hospital. Eleven of 16 patients(5 underwent only 1 course and so were excluded)received the SH-SP regimen between January 2012 and January 2018 to present and were included. Serum creatinine(Cr)and estimated glomerular filtration rate(eGFR)were used to assess renalfunction. Median course was 5. Rate of 5-course accomplishment was 72.7%. Grade 1 Cr elevation was observed in only 3 patients and there was no severe renal disorder. The SHSP regimen could be administered in outpatient settings and was considered safe as it did not cause renal toxicity.